2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer (10/27/2009)
Researchers from Spain have reported that neoadjuvant Taxotere® (docetaxel) and androgen deprivation therapy (ADT) was well tolerated and associated with a 6% pathological complete response (pCR) rate and a 6% near pCR rate in men with high-risk prostate cancer. The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.

New Oral Agent, Tasquinimod, May Have Activity in Prostate Cancer (10/26/2009)
Researchers from Sweden have reported that tasquinimod, an oral analog of linomide, may have significant activity in men with hormone-refractory prostate cancer (HRPC). The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.

Relative Effectiveness of Minimally Invasive Prostatectomy vs Open Prostatectomy Debated (10/15/2009)
Researchers from Harvard University have reported that men undergoing minimally invasive radical prostatectomy (MIRP) have “a shorter hospital stay, fewer respiratory and miscellaneous surgical complications and strictures, and similar postoperative use of additional cancer therapies but experienced more genitourinary complications, incontinence, and erectile dysfunction” than men undergoing conventional open retropubic prostatectomy (RRP). The details of this study appeared in the October 14, 2009 issue of the Journal of the American Association.

Radium-223 (Alpharadin®) Effective Palliation for Prostate Cancer Metastatic to Bone (10/9/2009)
Researchers involved in three Phase II European multicenter studies have reported that Alpharadin® (radium-223), an alpha emitter, is effective and well tolerated for the treatment of men with hormone refractory prostate cancer (HRPC) with metastatic bone lesions. The details of these studies were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24 2009.

Dutasteride Effective in Reducing Risk of Prostate Cancer in High-risk Men (10/8/2009)
Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, have reported that dutasteride, a 5-alpha-reductase inhibitor that inhibits conversion of testosterone into dihydrotestosterone, is effective in reducing the risk of biopsy-proven prostate cancer in men with an elevated prostate specific antigen (PSA) with negative prostate biopsies. The details of this study were reported at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24.